Company news
Theraclion Sa (EURONEXT:ALTHE) news
Theraclion Sa news releases on 6ix. Latest, Sep 16, 2026: 2026 Half-Year Results: Theraclion Prepares for a New Stage in Its Development
Press releases & updates
2026 Half-Year Results: Theraclion Prepares for a New Stage in Its Development
September 16, 2026
Theraclion Initiates Its Commercial Momentum in the First Half of 2026
July 23, 2026
Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL
July 15, 2026
Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors
July 9, 2026
Theraclion Announces the Evolution of Its Board of Directors
June 18, 2026
Theraclion Secures Key U.S. Reimbursement Milestone for Sonovein® With AMA CPT Editorial Panel Approval of a New Category III CPT Code
June 8, 2026
Theraclion Announces First Clinical Deployment of Sonovein® in Hainan, China
June 4, 2026
Theraclion Announces the Success of the First International HIFU Congress in Parma, Where Promising Preliminary Results From Its Sonovein® SpeedPulse Were Presented
June 1, 2026
Theraclion Announces the Strong Success of Its Oversubscribed Capital Increase
May 11, 2026
Theraclion Announces the Launch of a Capital Increase Through the Issuance of ABSA (Shares With Share Warrants Attached), With Preferential Subscription Rights for Existing Shareholders, for a Gross Amount of €6 Million, Secured by Subscription...
April 20, 2026
Theraclion Publishes Its 2025 Financial Results and Provides an Update on Its Outlook
April 16, 2026
Theraclion Delivers a Structuring Year in 2025 and Prepares to Scale up
January 29, 2026
Theraclion Announces Sonovein FDA Submission Following a Strong Year of Regulatory and Clinical Achievements
December 9, 2025
Theraclion Reports Major Recent Developments and Announces Its 2025 Half-Year Financial Results
October 29, 2025
Theraclion Secures Key Chinese Certification, Advancing Toward Market Access in China
October 21, 2025
Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital
October 10, 2025
Theraclion: Sonovein® Receives MDR Certification, Strengthening Its Commercial Potential
September 24, 2025
Theraclion Announces Successful U.S. FDA Pivotal Study With 96.8% Occlusion Rate
September 15, 2025
Theraclion Growth Up in S1 2025
July 25, 2025
Theraclion Announces Financial Results 2024 and Reviews Progress
April 29, 2025
Theraclion Completes Its Previous Financing Round With an Additional Convertible Bonds Issuance
March 26, 2025
Theraclion Secures Financing From Its Historical Shareholders Through a Convertible Bond Loan
February 20, 2025
Theraclion Announces Treatment of First Patients With New SONOVEIN® ‘SpeedPulse’ Feature Accelerating Treatment
February 11, 2025
Theraclion: Publication of Adjusted Accounts for the First Half of 2024
February 7, 2025
Theraclion Reviews Its 2024 Achievements
January 6, 2025
Theraclion Announces Major Advances and Reports First-Half Financial Results
October 30, 2024
Theraclion Confirms Strong Mid-Year Achievements
September 6, 2024
SONOVEIN® FDA Pivotal Study Treatments Completed: Theraclion Reaches Key Milestone on Schedule
June 24, 2024
Theraclion: SONOVEIN® Highlighted in Top Medical Conferences and Scientific Journal
June 6, 2024